Two-year Outcomes: the NOBORI™ Biolimus-Eluting versus XIENCE™/PROMUS™ Everolimus-eluting Stent Trial (NEXT)

**History:** One-year outcomes found Nobori Biolimus-eluting stent (BES) with biodegradable polymer statistically equivalent to durable polymer Xience/Promus Everolimus-eluting stent (EES).

**Questions to answer:** Does longer term surveillance provide further evidence of efficacy and safety of BES in comparison to EES?

**Trial Design**
- Phase IV, interventional, randomized 1:1 trial
- N=3,235; BES=1,617 vs. EES=1,618
- All-comer patients with planned PCI and drug-eluting stent placement

**Primary Endpoints**
- Efficacy: Target-lesion revascularization at 1 year
- Safety: All-cause death or myocardial infarction at 3 years

**Trial Results**
- Efficacy endpoint was observed in 6.2% of BES and 6.0% of EES patients.
- Safety endpoint was observed in 7.8% of BES and 7.7% of EES patients.

**Take Away:** At 2 years, BES remained non-inferior to EES in terms of both efficacy and safety. Surveillance for final 3 year outcomes will continue.

Presented by: Natsuaki et al., ACC.14, Washington, D.C. © 2014, American Heart Association. All rights reserved.